Table 1.
CXCR4 antagonists in clinical development.
| Drug Name | Phase | Active Indication | Combination Therapy | Trial number |
|---|---|---|---|---|
| Small Molecules | ||||
| Plerixafor (AMD3100) | Phase 3 | Myelokathexis | NCT02231879 | |
| Phase 1 | Pancreas, Ovarian, Colon Cancer | NCT3277209 | ||
| Phase 2 | Metastasis Pancreatic Cancer | Cemiplimab | NCT4177810 | |
| Phase 2 | Wiskott-Aldrich Syndrome, Hematopoietic Stem Cell Transplantation | NCT3019809 | ||
| Phase 2 | Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Busulfan, Cyclophosphamide | NCT2065460 | |
| Mavorixafor (AMD11070; X4P-001) | Phase 2/3 | WHIM Syndrome | NCT03005327 | |
| Phase 1 | Waldenestrom’s Macroglobulinemia | Ibrutinib | NCT04274738 | |
| Phase 1 | Melanoma | Pembrolizumab | NCT02823405 | |
| Phase 1/2 | Renal Cancer | axitinib | NCT02667886 | |
| USL311 | Phase 1/2 | Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2) | Lomustine | NCT02765165 |
| NOX-A12 | Phase 1/2 | Metastatic Colorectal Cancer Metastatic Pancreatic Cancer |
Pernbrolizurnab | NCT03168139 |
| CX-01 | Phase 1 | Myelodysplastic Syndromes, Acute Myeloid Leukemia |
Azacitidine | NCT02995655 |
| Phase 2 | Acute Myeloid Leukemia | ldarubicin, Cytarabine | NCT02873338 | |
| Peptide CXCR4 antagonists | ||||
| Balixafortide | Phase 3 | Metastatic Breast Cancer | Eribulin | NCT03786094 |
| LY2510924 | Phase 1 | Leukemia | Idracibin, Cytarabine | NCT02652871 |
| [68Ga]Pentixafor | Phase 1 | Neuroendocrine Tumors | NCT03335670 | |
| Early Phase | Multiple MyelomaLymphoma | NCT03436342 | ||
| BL-8040 | Phase 2 | Metastatic Pancreatic Adenocarcinorm |
Pernbrolizurnab | NCT02826486 |
| Phase 2 | Malignant Neoplasms of Digestive OrgansMetastatic Pancreatic Cancer | Pernbrolizurnab | NCT02907099 | |
| Phase 3 | Multiple Myeloma | NCT03246529 | ||
| Phase 1/2 | Pancreatic Adenocarcinorm | PEGPH20, Cobimetinib, Atezolizumab, Gemcitabine, Nab- Paclitaxet Oxaliplatin, Leucovorin, Fluorouracil |
NCT03193190 | |
| Phase 1/2 | Gastric Adenocarcinorm or Gastroesophageal Junction Adenocarcinorm | PEGPH20, Linagliptin, Paclitaxet, Ramucirumab, 5-Fluorouracil (5-FU) Leucovorin, Oxaliplatin, Atezolizurmab, Cobimetinib |
NCT03281369 | |
| Phase 1/2 | CarcinomaNon-Srmll-Cell Lung AtezolizurmhCobimetinih | Gemicitabine, Carboplatin, Pemetrexed, CPI-444, Tazemetostat, Atezolizumab, Cobimetinib, RO6958688, DOcetaxel |
NCT03337698 | |
| Anti-CXCR4 antibodies | ||||
|
Uloccuplumab (MDX-
1338) |
Phase 1/2 | Waldenstrom's Macroglobulinemia |
lbtutinib | NCT03225716 |
| Phase 1/2 | Leukemia | Cytarabine | NCT02305563 | |
| ALX-0651 | Phase 1 | Healthy Volunteers | NCT01374503 | |
| PF-06747143 | Phase 1 | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Azacitidine, Decitabine |
NCT02954653 |